Vivus, Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 11 of 11 Posts
3 Biotech Stocks Up In The Past Month On Industry Turnaround
Article By: Zacks Investment Research Tuesday, June 5, 2018 1:08 PM EST
After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front.
In this article: BMRN, LGND, VVUS Also: JNJ
Qualcomm, Inc., VIVUS, Inc. Beat Earnings Estimates
Article By: ValueWalk Wednesday, November 4, 2015 5:43 PM EST
Qualcomm reported adjusted earnings of 91 cents per share or $1.4 billion and $5.5 billion in revenue for its fourth fiscal quarter. Vivus posted losses of 15 cents per share and $24.9 million in revenues.
In this article: VVUS, QCOM
Shares Of Orexigen Soar After It Announces Improved Safety Results For Weight-Loss Drug
Article By: Terry Chrisomalis Tuesday, March 3, 2015 2:37 PM EST
Orexigen's drug Contrave shows not only shows great safety but also shows the ability to reduce heart-related problems as compared to placebo.
In this article: OREX, ARNA, VVUS
VIVUS Q4 Loss Wider Than Expected, Qsymia Disappoints
Article By: Zacks Investment Research Wednesday, February 25, 2015 11:56 AM EST
VIVUS Inc.’s fourth-quarter 2014 loss of 25 cents per share was wider than the Zacks Consensus Estimate loss by a penny and the year-ago loss of 9 cents.
In this article: VVUS
E Novo Nordisk's Saxenda Approved But Company Enters Into A Crowded Obesity Market
Article By: Terry Chrisomalis Friday, December 26, 2014 3:58 PM EST
Saxenda Approved by the FDA to treat Obesity but faces big obstacles against many competitors.
In this article: NVO, TKPHF, OREX, ARNA, VVUS
Ramifications Of Stendra's FDA Approved Label Extension
Article By: Retail Investor 360 Friday, September 19, 2014 1:36 PM EST
Great News to Investors and Patients, But What is Vivus's Ultimate Destiny
In this article: VVUS
Orexigen Received The FDA's Approval For Contrave Yet Questions Remain
Article By: Retail Investor 360 Thursday, September 11, 2014 6:33 PM EST
The FDA has approved Orexigen Therapeutics' (OREX) weight-management drug, Contrave. But is it a buy when similar products such as ARNA's Belviq, GSSK's Orlistat and VVUS's Qsymia – been unable to create traction in sales?
In this article: GSK, ARNA, OREX, VVUS
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind
Article By: Retail Investor 360 Tuesday, August 19, 2014 1:10 PM EST
360 Biotech's contrarian thesis on the weight loss drugs developer published in 2013 was unwelcoming but turned out valid. Stock promoters who were overly exuberant on Arena, Orexigen, and/or VIVUS mislead investors.
In this article: ARNA, MNKD, OREX, VVUS
VIVUS Inc: Can Stendra Extend The Company's Prospect
Article By: Retail Investor 360 Monday, August 18, 2014 6:58 AM EST
The Story. VIVUS FDA approved obesity drug, Qsymia, has better efficacy in terms of more weight reduction than Belviq, Contrave, and Orlistat.
In this article: ARNA, VVUS
E Orexigen Gets An Early Morning Surprise With FDA Delay For Contrave
Article By: Terry Chrisomalis Wednesday, June 11, 2014 8:58 AM EST
The FDA issued a delay for Orexigen's (OREX) obesity drug Contrave, The stock has now fallen by more than 15% in pre-market trading, creating an investment opportunity for patient investors.
In this article: ARNA, OREX, VVUS
Friday Options Recap
Article By: Fred Ruffy Friday, July 13, 2012 12:00 PM EST
Stock market averages are up sharply and led by the financials Friday.
In this article: BAC, BPI, DNR, ETN, JPM, PBY, PG, WFC, VVUS
1 to 11 of 11 Posts